Loading
The UK phase 3 trial that showed carboplatin is not better than docetaxel for triple-negative breast cancer as a whole, but is for the germline BRCA1/2 subgroup, and that gave the NHS its evidence for platinum in BRCA carriers.
TNT randomised women with metastatic or recurrent locally advanced triple-negative or BRCA1/2-associated breast cancer to carboplatin or docetaxel, crossing over at progression. Reported in Nature Medicine in 2018 with Andrew Tutt as first author, it found no advantage for carboplatin in the unselected triple-negative population but a doubling of response for germline BRCA1/2 carriers, and no benefit from BRCAness signatures in predicting platinum response. It was run by the Cancer Research UK funded Clinical Trials and Statistics Unit at the ICR.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Jean Abraham, Germline BRCA mutation (gBRCA), BRCA1 / BRCA2 (HRD), Platinum agents and the tags uk, breast.
Shares Jean Abraham, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC) and the tags uk, breast.
Shares Triple-negative breast cancer (TNBC) and the tags uk, breast.
Shares Andrew Tutt, Germline BRCA mutation (gBRCA), Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD).
Shares the tags uk, breast.
Shares the tags uk, breast.
Shares the tags uk, breast.
Shares Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD), Platinum agents, Carboplatin and the tag breast.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/